The complaint alleges that Moderna used the patented fluorescent protein technology without permission during preclinical through phase III trials and for marketing purposes, claiming the technology was critical for Moderna’s vaccine development success, which has generated over $47 billion in revenues.
The complaint alleges that Moderna used the patented fluorescent protein technology without permission during preclinical through phase III trials and for marketing purposes, claiming the technology was critical for Moderna’s vaccine development success, which has generated over $47 billion in revenues.
